@article{oai:repo.qst.go.jp:00085633,
 author = {Kuribayashi, Winnaung and Tsuji, Atsushi and Sugyo, Aya and Fujinaga, Masayuki and Ming-Rong, Zhang and Higashi, Tatsuya and Winnaung, Kuribayashi and Atsushi, Tsuji and Aya, Sugyo and Masayuki, Fujinaga and Zhang, Ming-Rong and Tatsuya, Higashi},
 issue = {15},
 journal = {International Journal of Molecular Sciences},
 month = {Aug},
 note = {Photoimmunotherapy (PIT) is an upcoming potential cancer treatment modality, the effect of which is improved in combination with chemotherapy. PIT causes a super-enhanced permeability and retention (SUPR) effect. Here, we quantitatively evaluated the SUPR effect using radiolabeled drugs of varying molecular weights (F-5FU, In-DTPA, Tc-HSA-D, and In-IgG) to determine the appropriate drug size. PIT was conducted with an indocyanine green-labeled anti-HER2 antibody and an 808 nm laser irradiation. Mice were subcutaneously inoculated with HER2-positive cells in both hindlimbs. The tumor on one side was treated with PIT, and the contralateral side was not treated. The differences between tumor accumulations were evaluated using positron emission tomography or single-photon emission computed tomography. Imaging studies found increased tumor accumulation of agents after PIT. PIT-treated tumors showed significantly increased uptake of F-5FU ( < 0.001) and Tc-HSA-D ( < 0.001). A tendency toward increased accumulation of In-DTPA and In-IgG was observed. These findings suggest that some low- and medium-molecular-weight agents are promising candidates for combined PIT, as are macromolecules; hence, administration after PIT could enhance their efficacy. Our findings encourage further preclinical and clinical studies to develop a combination therapy of PIT with conventional anticancer drugs.},
 title = {Quantitative Radionuclide Imaging Analysis of Enhanced Drug Delivery Induced by Photoimmunotherapy},
 volume = {22},
 year = {2021}
}